Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
The Financial Times9d
Obesity drug sales surge at Novo Nordisk
Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe’s most valuable listed company almost 5 per cent higher.
MedCity News9d
Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects
Last September, Novo Nordisk reported Phase 2 obesity study results showing ... said Wednesday that it is evaluating this drug for further clinical development in this indication.
AOL12d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Drugmakers have poured small fortunes into the development ... Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug ...
Reuters9d
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity ... obesity drug Wegovy, Martin Holst Lange, Novo Nordisk's executive vice president for development, said ...
Investors Seek Answers on Novo Nordisk's Next-Gen Obesity Drug CagriSema
LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...